



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Zamerovimab

Cat. No.:	HY-P99513
CAS No.:	2419087-87-7
Target:	RABV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Zamerovimab (CTB011; SYN023) is a mixture of human monoclonal antibodies consisting of CTB011 and CTB012. Zamerovimab binds to non-overlapping epitopes on rabies virus (RABV) glycoprotein, where CTB011 binds to antigenic site III. Zamerovimab can be used in rabies studies ^[1] .
In Vitro	Zamerovimab (CTB011; SYN023) (0.001-100 µg/mL, 4 h) can induce cytotoxicity and promote viral clearance in a dose-dependent manner in CVS-infected BSR cells, also suggesting that cytotoxicity is associated with the specificity of cells expressing G proteins that are targeted by CTB011 ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Zamerovimab (CTB011; SYN023) (0.03-1.0 mg/kg, right gastrocnemius injection, once, 35 days) can increase the survival of Syrian hamsters infected with RABV BD06 virus in a dose-dependent manner, with survival rates of 58%, 83%, 100% and 100% at doses of 0.03, 0.1, 0.3 and 1.0 mg/kg, respectively ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Tzu-Yuan Chao, et al. SYN023, a novel humanized monoclonal antibody cocktail, for post-exposure prophylaxis of rabies. PLoS Negl Trop Dis. 2017 Dec 20;11(12):e0006133.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA